Decoy Therapeutics Inc. (DCOY)
Nasdaq: DCOY · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2014
Who owns Decoy Therapeutics Inc.
As filed with the SECHolders of 5% or more
2
Armistice Capital, LLC holds 9.99% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G filed Aug 14, 2026 says.
Directors and officers
10
report now, of 30 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Armistice Capital, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share
CVI Investments, Inc.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · 9.9% in Nov 18, 2025
Mitchell P. Kopin
SCHEDULE 13G · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
C/M Capital Master Fund, LP
SCHEDULE 13G · filed Oct 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
What DCOY reports owning in othersstakes of 5% or more, and other ties
Decoy Therapeutics Inc. reports no stake in another company in the record.
Insider tradesForm 4
2sales
2purchases
0sales on a scheduled plan
1people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 32 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Rosenblum Mark J | Chief Financial Officer | 0 | $0 | 0 | 1 | $0 |
| Hanish Arnold C | director | 2 | $0 | 0 | 1 | $0 |